Realizing the nano-amorphous state of materials inside nano-porous templates

Patent metadata

Field	Value
Publication number	US-12458602-B2
Application number	US-202117313528-A
Country	US
Kind code	B2
Filing date	May 6, 2021
Priority date	May 6, 2021
Publication date	Nov 4, 2025
Grant date	Nov 4, 2025

Abstract

The subject invention pertains to methods to produce amorphous materials at nanometer scale, by solidifying or hardening the materials inside nanometer-sized pores of porous media (i.e., porous templates). The porous templates can be made by packing nanometer-sized particles or other means. The subject invention further pertains to methods to produce the porous templates used to produce amorphous material at nanometer scale.

First claim

We claim:

1 . A method for producing nano-amorphous composite materials, the method comprising:
i) providing an active compound; ii) providing a porous template made by agglomerating silica nanoparticles in an aqueous colloidal suspension and drying to preserve the porous template in dry conditions; iii) melting, grinding, suspending, or dissolving the active compound in a solution to yield a ground active compound, a melted active compound, a suspended active compound, or a dissolved active compound; iv) loading the ground active compound, melted active compound, dissolved active compound, or suspended active compound into the porous template to form an active compound loaded template; v) pressing the active compound loaded porous template; and vi) heating the active compound loaded porous template to form a composite material of the active compound absorbed in pores of the agglomerated silica nanoparticles wherein all of the active compound is in an amorphous state.

2 . The method of claim 1 , wherein the silica nanoparticles in the aqueous colloidal suspension have a particle size of 1 nm to 100 nm.

3 . The method of claim 1 , wherein the active compound is a drug, wherein the drug is a water-insoluble drug.

4 . The method of claim 3 , wherein the drug is any of Ibuprofen, Ketoprofen, Flurbiprofen, Diclofenac, Oxaprozin, Indomethacin, Naproxen, Trimebutine, Fenofibrate, Econazole, and Ramipril.

5 . The method of claim 1 , wherein the aqueous colloidal suspension further comprises a stabilizer, wherein the stabilizer is ammonium, sodium ion, or a combination thereof.

6 . The method of claim 1 , wherein step iv) further comprises mixing the dry template and the active compound and grinding the mixed dry template and the active compound into a powder with a particle size of about 0.1 μm to about 1000 μm.

7 . The method of claim 6 , further comprising compressing the mixed dry template and the active compound powder together into tablets.

8 . The method of claim 1 , further comprising melting of the active compound at a temperature at or above a melting point of the active compound and maintaining the temperature during the loading of the melted active compound into the porous template.

9 . The method of claim 1 , wherein after the ground, melted, dissolved, or suspended active compound is loaded into the porous template, the method further comprises:
vii) cooling the loaded ground, melted, dissolved, or suspended active compound in the porous template to below a melting point of the active compound to about 18° C. to about 28° C. or to about room temperature and/or removing the solvent after the active compound is loaded into the porous template.

Assignees

• Univ Hong Kong Chinese
• Harvard College

Inventors

• Xu Lei
• Weitz David
• Xu Zhuo
• Zhu Changliang

Classifications

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K9/2009 Primary

  Inorganic compounds · CPC title

• A61K9/2031

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers · CPC title

• A61K9/2027

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title